Mstarin 25mg Capsule

About

Mstarin 25mg Capsule is a highly effective targeted therapy, specifically a potent tyrosine kinase inhibitor (TKI), engineered to selectively block the activity of the Bcr-Abl fusion protein. This abnormal protein is the defining characteristic and oncogenic driver of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). By inhibiting the constitutively active tyrosine kinase activity of Bcr-Abl, Mstarin disrupts the signaling pathways essential for the uncontrolled proliferation and survival of CML cells. This precise mechanism leads to a significant reduction in malignant cell burden, normalization of blood cell counts, and induction of deep molecular and cytogenetic remissions in patients. It is primarily indicated for the treatment of newly diagnosed Ph+ CML in the chronic phase, and for Ph+ CML in chronic or accelerated phase in adult patients who have demonstrated resistance or intolerance to prior TKI therapies, offering a crucial therapeutic option.

Uses

• Newly diagnosed Ph+ CML (chronic phase)
• Ph+ CML (chronic or accelerated phase)
• CML resistant to prior TKI therapy
• CML intolerant to prior TKI therapy

Directions For Use

Take orally twice daily on an empty stomach, at least 2 hours after and 1 hour before food. Swallow capsules whole.

Benefits

• Highly effective in Ph+ CML.
• Induces deep molecular responses.
• Improves progression-free and overall survival.
• Oral administration for convenience.
• Targets the underlying cause of CML.
• Option for resistant/intolerant patients.

Side Effects

• Myelosuppression (neutropenia, thrombocytopenia)
• Nausea and vomiting
• Diarrhea
• Fatigue
• Headache
• Rash
• Elevated liver enzymes
• Fluid retention (edema)
• Muscle pain
• QT prolongation (cardiac)
• Pancreatitis
• Hyperglycemia

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may increase the risk of liver toxicity or gastrointestinal upset.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm; use effective contraception during treatment and for a period after.
• Breastfeeding - Advise against breastfeeding due to the potential for serious adverse reactions in breastfed infants.
• Liver - Use with caution in patients with hepatic impairment; dose adjustment may be necessary.
• Kidney - Use with caution in patients with renal impairment; monitor kidney function closely.
• Lung - Monitor for new or worsening pulmonary symptoms, including pleural effusion or interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.